Literature DB >> 2942318

Decrease in helper (T4+) lymphocytes following cimetidine treatment for duodenal ulcer.

R Hast, P Bernell, R Befrits, C Dowding, A M Sjögren.   

Abstract

We studied the possible in vivo influence of cimetidine on peripheral blood lymphocyte (PBL) subpopulations defined with monoclonal antibodies (MoAb) in eight haematologically normal patients with uncomplicated duodenal ulcers before cimetidine treatment, 1 week after the start, and finally 1 week following cessation of therapy. After cimetidine had been given for 3-5 weeks there was a significant decrease, compared with pretreatment numbers, in the proportion of T3+ cells (64.6 +/- 8.1 (mean +/- s.d.) v 51.0 +/- 7.8%) and in T4+ cells (47.3 +/- 4.3 v 30.8 +/- 4.7%). The number of T8+ cells was not affected (20.3 +/- 4.3 v 20.1 +/- 6.7%). These changes resulted in a significant reduction in the T4/T8 ratio (2.46 +/- 0.8 v 1.67 +/- 0.6). The total numbers of lymphocytes and monocytes as well as the percentage of B1+ lymphocytes did not change significantly. The observed decrease in T4/T8 ratio after cimetidine treatment is explained by a reduction in the number of T4+ cells and the appearance of a new subpopulation of T3-, T4-, T8-, B1-lymphocytes. The underlying mechanism, however, is not clear. Cimetidine does not seem to have a direct receptor-modulating effect, since in vitro exposure of normal lymphocytes to the drug did not change the proportions of the T cell subsets.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942318      PMCID: PMC1542163     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

Review 1.  Histamine-induced suppressor-cell activity.

Authors:  D J Beer; R E Rocklin
Journal:  J Allergy Clin Immunol       Date:  1984-04       Impact factor: 10.793

2.  The effect of cimetidine treatment on suppressor T cells in duodenal ulcer patients.

Authors:  H Tchórzewski; K Markiewicz; P Malec
Journal:  Immunol Lett       Date:  1984       Impact factor: 3.685

Review 3.  Are there immunologic forms of duodenal ulcer?

Authors:  J I Rotter; D C Heiner
Journal:  J Clin Lab Immunol       Date:  1982-01

4.  Peripheral blood T lymphocytes in patients with duodenal ulcers treated with cimetidine.

Authors:  M R Gigi; E Akriviadis; I Agorastos; G Goulis
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

5.  Lymphocyte subpopulations in gastric disease; effect of histamine and cimetidine on immunoregulatory T cell subsets.

Authors:  M Raptopoulou-Gigi; P Boura; N Valcanos; G Goulis
Journal:  J Immunopharmacol       Date:  1984

6.  Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF).

Authors:  R E Rocklin; J Breard; S Gupta; R A Good; K L Melmon
Journal:  Cell Immunol       Date:  1980-05       Impact factor: 4.868

7.  Liquid-chromatographic determination of cimetidine, its known metabolites, and creatinine in serum and urine.

Authors:  J A Ziemniak; D A Chiarmonte; J J Schentag
Journal:  Clin Chem       Date:  1981-02       Impact factor: 8.327

  7 in total
  4 in total

Review 1.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  B-cell and T-regulatory cell dysfunction in six Chinese children with hypogammaglobulinaemia.

Authors:  B M Jones; Y L Lau; K L Wong
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

3.  Modified lymphocyte response to mitogens after intraperitoneal injection of glycopeptidolipid antigens from Mycobacterium avium complex.

Authors:  P E Brownback; W W Barrow
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 4.  Cimetidine as an immune response modifier.

Authors:  R Hast; P Bernell; M Hansson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.